A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
Public ClinicalTrials.gov record NCT00463918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.
Study identification
- NCT ID
- NCT00463918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 73 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 16 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- Not listed
- Completion
- Nov 30, 2007
- Last update posted
- Nov 18, 2008
2007
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anniston | Alabama | 36201 | — |
| Pfizer Investigational Site | Anniston | Alabama | 36207 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85013 | — |
| Pfizer Investigational Site | Hot Springs | Arkansas | 71913 | — |
| Pfizer Investigational Site | Anaheim | California | 92801 | — |
| Pfizer Investigational Site | Los Angeles | California | 90211 | — |
| Pfizer Investigational Site | New Haven | Connecticut | 06511-5473 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32607 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96813 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96826 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66212 | — |
| Pfizer Investigational Site | Bardstown | Kentucky | 40004 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40509 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00463918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2008 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00463918 live on ClinicalTrials.gov.